Resource Center

Go back to Resource Center

Spectral Domain Optical Coherence Tomography Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2).

2020 Dec 26

Journal Article

Etheridge, T.; Blodi, B.; Oden, N.; Van Veldhuisen, P.; Scott, I.U.; Ip, M.S.; Mititelu, M.; Domalpally, A.

Ophthalmol Retina




Anti-VEGF; macular edema; retinal vein occlusion; Spectral Domain Optical Coherence Tomography; visual acuity

OBJECTIVE: To evaluate the association between baseline demographic and SD-OCT features with visual acuity (VA) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) over 2 years.DESIGN: Post-hoc analysis of prospective clinical trial data.PARTICIPANTS: 362 SCORE2 participants with macular edema secondary to central retinal (CRVO) or hemi-retinal vein occlusion (HRVO).METHODS: SD-OCT volume scans were assessed at the SCORE2 reading center at baseline, month 01 (M01), month 06 (M06), month 12 (M12), and month 24 (M24) for central subfield thickness (CST), subretinal fluid, intraretinal fluid, vitreoretinal interface abnormalities, disorganization of retinal inner layers (DRIL), and ellipsoid zone (EZ) within the central subfield (CSF).MAIN OUTCOME MEASURES: VA at M06, M12, and M24 RESULTS: Mean baseline age was 68.9 years. Mean VA at M01 was 63.2 letters and central subfield thickness was 299.7 microns. At M01, subretinal fluid was seen in 28.5% intraretinal fluid in 67.2%, DRIL was seen in 73.8%, mostly within CSF and EZ was absent in 9.8 and patchy in 31.7%. In multivariate analysis including all M01 demographics and SDOCT parameters and their association with VA at M06, M12 and M24, VA at M01 remained significant across all time points up to M24 (p<0.001).CONCLUSIONS: In this 2 year follow up of eyes that were treated with both per protocol and off protocol for RVO, visual acuity at M01 was an important predictor of long-term vision and change in vision. Establishing predictors of visual recovery helps identify causes for poor responders to treatment in patients with RVO.

Go back to Resource Center